XML 53 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Tax
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Tax

10. Income Tax

Significant components of the Company’s provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate were as follows (in thousands):

 

 

For the Year Ended December 31,

 

 

 

2023

 

 

2022

 

Statutory rate

 

$

(21,146

)

 

$

(18,715

)

State tax

 

 

(6,935

)

 

 

(6,005

)

Other permanent items

 

 

60

 

 

 

(50

)

Research and development credit

 

 

(3,405

)

 

 

(2,958

)

Change in valuation allowance

 

 

31,954

 

 

 

26,296

 

Stock-based compensation

 

 

(528

)

 

 

1,432

 

Provisions for income taxes

 

$

 

 

$

 

Significant components of the Company’s deferred taxes were as follows (in thousands):

 

 

As of December 31,

 

 

 

2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

75,803

 

 

$

64,031

 

Research and development credits

 

 

14,069

 

 

 

10,664

 

Stock-based compensation

 

 

10,538

 

 

 

6,249

 

Accruals and other

 

 

1,635

 

 

 

1,794

 

Intangible assets

 

 

6,713

 

 

 

7,274

 

Capitalized research expense

 

 

24,028

 

 

 

11,229

 

Lease liability

 

 

2,858

 

 

 

3,385

 

Gross deferred tax assets

 

 

135,644

 

 

 

104,626

 

Less valuation allowance

 

 

(132,965

)

 

 

(101,445

)

Total deferred tax assets

 

 

2,679

 

 

 

3,181

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Property and equipment

 

 

(120

)

 

 

(106

)

Right-of-use assets

 

 

(2,559

)

 

 

(3,075

)

Total deferred tax liabilities

 

 

(2,679

)

 

 

(3,181

)

Deferred income taxes, net

 

$

 

 

$

 

A valuation allowance of $133.0 million at December 31, 2023, has been recognized to offset the net deferred tax assets as realization of such assets is uncertain. The valuation allowance increased by $31.5 million during the year ended December 31, 2023.

As of December 31, 2023, the Company had available net operating loss (NOL) carryforwards of $242.1 million. Of the $242.1 million of NOL carryforwards, $41.6 million begin to expire in 2034 and $200.5 million do not expire. The Company also has available California NOL carryforwards of approximately $356.0 million as of December 31, 2023, which begin to expire in 2034. In addition, the Company has federal and California research and development (R&D) credit carryforwards totaling $11.8 million and $6.2 million, respectively. The federal credits begin to expire in 2034 unless previously utilized, while the state credits do not expire.

Pursuant to Sections 382 and 383 of the Internal Revenue Code (IRC), annual use of the Company’s NOL and credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Since the Company’s formation, the Company has raised capital through the issuance of capital stock, which on its own or combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership.

Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the Company’s NOL and research and development credit carryforwards are subject to an annual limitation, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could be subject to

additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. The Company has not completed an analysis to determine if such an ownership change has occurred.

The Company recognizes liabilities for uncertain tax positions based in a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.

The following table summarized activity related to the Company's gross unrecognized tax benefits (in thousands):

 

 

For the Year Ended December 31,

 

 

 

2023

 

 

2022

 

Beginning balance

 

$

2,172

 

 

$

1,614

 

Increases related to current year tax positions

 

 

639

 

 

 

558

 

Ending balance

 

$

2,811

 

 

$

2,172

 

As of December 31, 2023, the Company had gross unrecognized tax benefits of $2.8 million, none of which would affect the effective tax rate if recognized. The Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. The Company’s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its balance sheets at December 31, 2023 and has not recognized interest and/or penalties in its statement of operations for the year ended December 31, 2023.

The Company is subject to taxation in the United States and California. The Company is not currently under examination by any taxing authorities. Due to the carryover of tax attributes, the statute of limitations is currently open for tax years since inception.